Cantargia’s Immuno-oncology Project CAN04 Shows Promise in Additional Cancer Forms

Cantargia AB today announces that the company has generated novel data showing high levels of interleukin-1 receptor accessory protein (IL1RAP) in tumors from patients with liver cancer, esophageal cancer as well as head and neck cancer. In addition, Cantargia’s lead candidate CAN04, an IL1RAP binding antibody in clinical trials, showed potent antitumor activity in in vitro models of these cancer forms.

http://www.prnewswire.co.uk/news-releases/cantargias-immuno-oncology-project-can04-shows-promise-in-additional-cancer-forms-682771891.html

Leave a comment



Leave a Reply

Your email address will not be published. Required fields are marked *